BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 34304386)

  • 1. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone.
    Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Sin Y; Akane S; Sugaya J; Mori T; Fukushima S; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2021 Nov; 34(6):1899-1910. PubMed ID: 34304386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone.
    Ono T; Noguchi R; Yoshimatsu Y; Tsuchiya R; Sin Y; Nakagawa R; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2022 Jan; 35(1):392-399. PubMed ID: 34731453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone.
    Ono T; Noguchi R; Yoshimatsu Y; Sin Y; Tsuchiya R; Akiyama T; Kojima N; Toda Y; Sato C; Fukushima S; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2023 Sep; 36(5):1804-1812. PubMed ID: 37328637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone.
    Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2020 Oct; 33(4):1321-1328. PubMed ID: 32815117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1.
    Adachi Y; Noguchi R; Yoshimatsu Y; Sin Y; Osaki J; Ono T; Iwata S; Akiyama T; Tsuchiya R; Toda Y; Ishihara S; Ogura K; Kobayashi E; Kojima N; Yoshida A; Yokoo H; Kawai A; Kondo T
    Hum Cell; 2024 May; 37(3):874-885. PubMed ID: 38466561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone.
    Akiyama T; Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Fukushima S; Toda Y; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2022 Sep; 35(5):1621-1629. PubMed ID: 35653034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
    Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
    Ratnagiri R; Uppin S
    J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells.
    Fellenberg J; Sähr H; Mancarella D; Plass C; Lindroth AM; Westhauser F; Lehner B; Ewerbeck V
    Cancer Lett; 2019 Apr; 448():61-69. PubMed ID: 30742944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway.
    Lübbehüsen C; Lüke J; Seeling C; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Möller P; Barth TFE
    Sci Rep; 2019 Apr; 9(1):6458. PubMed ID: 31015476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
    Amary F; Berisha F; Ye H; Gupta M; Gutteridge A; Baumhoer D; Gibbons R; Tirabosco R; O'Donnell P; Flanagan AM
    Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
    Tsukamoto Y; Futani H; Kihara T; Watanabe T; Kumanishi S; Matsuo S; Hirota S; Ueda T; Yamamoto H; Yoshiya S
    Pathol Res Pract; 2018 Sep; 214(9):1504-1509. PubMed ID: 29970305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symplastic/pseudoanaplastic giant cell tumor of the bone.
    Sarungbam J; Agaram N; Hwang S; Lu C; Wang L; Healey J; Hameed M
    Skeletal Radiol; 2016 Jul; 45(7):929-35. PubMed ID: 27020452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H; Ishihara S; Toda Y; Oda Y
    Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
    Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
    Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
    Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
    Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
    Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
    Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
    Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
    Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
    Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors.
    Nohr E; Lee LH; Cates JM; Perizzolo M; Itani D
    Hum Pathol; 2017 Oct; 68():119-127. PubMed ID: 28882701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.